DK3449934T3 - Behandling af glycogenlagringssygdom type II - Google Patents

Behandling af glycogenlagringssygdom type II Download PDF

Info

Publication number
DK3449934T3
DK3449934T3 DK18194771.4T DK18194771T DK3449934T3 DK 3449934 T3 DK3449934 T3 DK 3449934T3 DK 18194771 T DK18194771 T DK 18194771T DK 3449934 T3 DK3449934 T3 DK 3449934T3
Authority
DK
Denmark
Prior art keywords
storage disease
disease type
treatment
glycogen storage
glycogen
Prior art date
Application number
DK18194771.4T
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3449934(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of DK3449934T3 publication Critical patent/DK3449934T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK18194771.4T 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II DK3449934T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
EP16178390.7A EP3108895B1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii

Publications (1)

Publication Number Publication Date
DK3449934T3 true DK3449934T3 (da) 2020-06-29

Family

ID=22818451

Family Applications (5)

Application Number Title Priority Date Filing Date
DK16178390.7T DK3108895T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK18194771.4T DK3449934T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK07001091.3T DK1782825T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK14167882.1T DK2767291T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK01951000T DK1301201T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenosis type II

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK16178390.7T DK3108895T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK07001091.3T DK1782825T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK14167882.1T DK2767291T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK01951000T DK1301201T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenosis type II

Country Status (17)

Country Link
US (10) US7056712B2 (da)
EP (4) EP2767291B1 (da)
JP (10) JP5113312B2 (da)
AT (1) ATE355075T1 (da)
AU (3) AU7194101A (da)
BR (1) BR0113006A (da)
CA (1) CA2416492C (da)
CY (2) CY1120977T1 (da)
DE (1) DE60126947T2 (da)
DK (5) DK3108895T3 (da)
ES (5) ES2700865T3 (da)
LT (3) LT3449934T (da)
MX (1) MXPA03000474A (da)
PT (5) PT3449934T (da)
SI (3) SI3449934T1 (da)
TW (1) TWI280882B (da)
WO (1) WO2002005841A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2767291B1 (en) * 2000-07-18 2016-09-14 Duke University Treatment of glycogen storage disease type II
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
ES2371913T3 (es) 2003-01-22 2012-01-11 Duke University Constructos mejorados para expresar polipéptidos lisosomales.
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
EP2099523A2 (en) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
ES2535461T3 (es) 2008-07-08 2015-05-11 Duke University Método de tratamiento de la enfermedad por almacenamiento de glucógeno
EP3679942A1 (en) * 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
CN115120746A (zh) 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
CN114540327B (zh) 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
EP3292871B1 (en) * 2015-05-07 2021-06-23 The University of Tokyo Nanoreactor using polyion complex polymersomes, and method for producing same
EP3344337A4 (en) * 2015-08-31 2019-03-06 Duke University METHOD AND COMPOSITIONS FOR TREATING CYTOPLASMATIC GLYCOGEN MEMORY DISEASES
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR20250007693A (ko) 2015-12-30 2025-01-14 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
AU2017239641A1 (en) 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
SG10201912761UA (en) 2016-04-15 2020-02-27 The Trustees Of The Univ Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
SMT202300187T1 (it) 2017-05-15 2023-07-20 Amicus Therapeutics Inc Alfa-glucosidasi acida umana ricombinante
KR102883778B1 (ko) 2017-09-22 2025-11-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
IT202300005733A1 (it) * 2023-03-27 2024-09-27 St Microelectronics Int Nv Circuito di comunicazione, sistema e procedimento corrispondenti

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
AU4072499A (en) 1998-05-13 1999-11-29 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
ES2312222T3 (es) * 1998-12-07 2009-02-16 Genzyme Corporation Tratamiento de la enfermedad de pompe.
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
EP2767291B1 (en) * 2000-07-18 2016-09-14 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
JP2013231081A (ja) 2013-11-14
SI3449934T1 (sl) 2020-09-30
AU2001271941B2 (en) 2007-03-01
EP3108895B1 (en) 2018-09-19
ATE355075T1 (de) 2006-03-15
PT2767291T (pt) 2016-10-25
US20150004152A1 (en) 2015-01-01
AU2010200487A1 (en) 2010-03-04
JP5792774B2 (ja) 2015-10-14
ES2799882T3 (es) 2020-12-22
EP3449934A1 (en) 2019-03-06
EP3108895A1 (en) 2016-12-28
DK1301201T3 (da) 2007-04-02
JP2017137357A (ja) 2017-08-10
JP2008081507A (ja) 2008-04-10
US7056712B2 (en) 2006-06-06
US20160184410A1 (en) 2016-06-30
US20020110551A1 (en) 2002-08-15
EP1301201A1 (en) 2003-04-16
ES2277931T3 (es) 2007-08-01
DE60126947T2 (de) 2007-10-31
WO2002005841A1 (en) 2002-01-24
US20130195834A1 (en) 2013-08-01
LT3108895T (lt) 2018-11-26
US20080175833A1 (en) 2008-07-24
PT1782825E (pt) 2014-11-04
US20210169996A1 (en) 2021-06-10
EP2767291A2 (en) 2014-08-20
TWI280882B (en) 2007-05-11
ES2700865T3 (es) 2019-02-19
DE60126947D1 (de) 2007-04-12
US20050123531A1 (en) 2005-06-09
EP2767291B1 (en) 2016-09-14
US20100254966A1 (en) 2010-10-07
LT3449934T (lt) 2020-08-10
PT3108895T (pt) 2018-12-18
DK2767291T3 (da) 2016-12-05
SI3108895T1 (sl) 2019-01-31
US8900552B2 (en) 2014-12-02
DK1782825T3 (da) 2014-11-03
JP2012006953A (ja) 2012-01-12
CA2416492C (en) 2008-04-29
JP2018199721A (ja) 2018-12-20
LT2767291T (lt) 2016-11-25
US9370556B2 (en) 2016-06-21
HK1103363A1 (en) 2007-12-21
JP6163216B2 (ja) 2017-07-12
JP2014185187A (ja) 2014-10-02
EP3449934B1 (en) 2020-05-20
JP2018002749A (ja) 2018-01-11
US20180185457A1 (en) 2018-07-05
JP2020019822A (ja) 2020-02-06
CY1123084T1 (el) 2021-10-29
PT3449934T (pt) 2020-06-25
DK3108895T3 (da) 2018-11-26
EP1301201B1 (en) 2007-02-28
ES2523024T3 (es) 2014-11-20
MXPA03000474A (es) 2003-10-06
US10792341B2 (en) 2020-10-06
CY1120977T1 (el) 2019-12-11
BR0113006A (pt) 2004-10-19
JP5113312B2 (ja) 2013-01-09
US20120058132A1 (en) 2012-03-08
JP2004503598A (ja) 2004-02-05
EP2767291A3 (en) 2014-10-08
HK1054690A1 (en) 2003-12-12
HK1197656A1 (en) 2015-02-06
JP2016056206A (ja) 2016-04-21
SI2767291T1 (sl) 2016-11-30
CA2416492A1 (en) 2002-01-24
US9907839B2 (en) 2018-03-06
AU7194101A (en) 2002-01-30
PT1301201E (pt) 2007-03-30
ES2599401T3 (es) 2017-02-01

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
EA200201214A1 (ru) Замещенные тиоацетамиды
DK2017276T3 (da) Phenylcarboxamid-forbindelser til behandling af smerte
EA200400530A1 (ru) Перекрестно-сшитые антибиотики "гликопептид-цефалоспорин"
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
SE0003476D0 (sv) Compounds
ATE422892T1 (de) Verwendung von hyaluronsäure zur herstellung von zusammensetzungen zur behandlung rekurrenten aphthen in der mundhöhle
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
ATE285775T1 (de) Behandlung diabetischer ulcera
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
ATE502639T1 (de) 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel
CY1118235T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ii
ATE306940T1 (de) Zusammensetzung gegen coccidiose